

**Clinical trial results:**

**A prospective randomised controlled phase III trial of gemcitabine and docetaxel compared with doxorubicin as first line treatment in previously untreated advanced unresectable or metastatic soft tissue sarcomas**

**Summary**

EudraCT number	2009-014907-29
Trial protocol	GB
Global end of trial date	08 May 2019

**Results information**

Result version number	v1 (current)
This version publication date	21 May 2020
First version publication date	21 May 2020
Summary attachment (see zip file)	GeDDiS publication (GeDDiS_publication_LancetOncology_20170904.pdf)

**Trial information****Trial identification**

Sponsor protocol code	UCL/09/0060
-----------------------	-------------

**Additional study identifiers**

ISRCTN number	ISRCTN07742377
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-
Other trial identifiers	UK CTA number: 20363/0285/001-0001, Swiss CTA number: 2013DR3049

Notes:

**Sponsors**

Sponsor organisation name	University College London
Sponsor organisation address	Joint Research Office, Gower Street , London , United Kingdom, WC1E 6BT
Public contact	ctc.sponsor@ucl.ac.uk, University College London, 020 76799264, ctc.geddis@ucl.ac.uk
Scientific contact	ctc.sponsor@ucl.ac.uk, University College London, 020 76799264, ctc.geddis@ucl.ac.uk

Notes:

**Paediatric regulatory details**

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

---

### Results analysis stage

Analysis stage	Final
Date of interim/final analysis	07 April 2017
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	08 May 2019
Was the trial ended prematurely?	No

Notes:

---

### General information about the trial

Main objective of the trial:

The principal research objective is to compare the efficacy and effectiveness of gemcitabine and docetaxel with that of doxorubicin.

Protection of trial subjects:

The risks for patients in this trial were similar to those for any patient undergoing chemotherapy treatment.

The eligibility criteria were stringent to ensure patients were fit enough to receive treatment, assessments during and after trial treatment were comprehensive and detailed guidance was given in the protocol for dose modifications if/when toxicity from the chemotherapy occurred. Adverse events pertaining to the administration of these drugs were closely monitored throughout the trial. Each patient's GP was informed of their participation and asked to report all serious side effects immediately to the research team at site. Patient cards were also issued to the patients in case of emergencies, which contained information about the trial and contact details of the hospital where they were being treated.

A risk assessment was performed for this trial and an appropriate level of monitoring was carried out, including the monitoring of patient safety.

Safety information was presented to the Trial Management Group, Data Monitoring Committee and Trial Steering Committee on a regular basis.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	25 November 2010
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

---

### Population of trial subjects

#### Subjects enrolled per country

Country: Number of subjects enrolled	United Kingdom: 249
Country: Number of subjects enrolled	Switzerland: 8
Worldwide total number of subjects	257
EEA total number of subjects	249

Notes:

---

**Subjects enrolled per age group**

---

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	197
From 65 to 84 years	60
85 years and over	0

---

## Subject disposition

### Recruitment

Recruitment details:

257 patients were recruited in total, 249 within the United Kingdom and 8 in Switzerland. The trial was opened to recruitment on 25/11/2010, the first patient was recruited on 03/12/2010, the final patient was recruited on 20/01/2014.

### Pre-assignment

Screening details:

497 patients were screened.

Patients were excluded due to one of the following reasons: did not meet eligibility criteria, patient decision (declined information sheet, recruitment appointment or randomisation), patient died before enrolment, patient treated at different hospital, clinical decision.

### Period 1

Period 1 title	Overall trial (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Not blinded

Blinding implementation details:

N/A

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	GemcitabineDocetaxel

Arm description:

Gemcitabine 675 mg/m<sup>2</sup> i.v. days 1 and 8, docetaxel 75 mg/m<sup>2</sup> i.v. day 8 every three weeks for up to 6 cycles

Arm type	Experimental
Investigational medicinal product name	gemcitabine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Gemcitabine 675 mg/m<sup>2</sup> i.v. days 1 and 8 every three weeks, for up to 6 cycles

Investigational medicinal product name	docetaxel
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Docetaxel 75 mg/m<sup>2</sup> i.v. day 8 every three weeks for up to 6 cycles

<b>Arm title</b>	Doxorubicin
------------------	-------------

Arm description:

Doxorubicin 75 mg/m<sup>2</sup> i.v. day 1 every three weeks for up to 6 cycles

Arm type	Active comparator
Investigational medicinal product name	doxorubicin
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for infusion
Routes of administration	Intravenous use

---

Dosage and administration details:

Doxorubicin 75 mg/m<sup>2</sup> i.v. day 1 every three weeks for up to 6 cycles

<b>Number of subjects in period 1</b>	GemcitabineDocetaxel	Doxorubicin
Started	128	129
Completed	49	71
Not completed	79	58
Adverse event, serious fatal	1	3
Physician decision	5	4
Consent withdrawn by subject	1	1
death	3	2
other reasons/unknown	11	7
Adverse event, non-fatal	14	1
did not start treatment	2	1
intercurrent illness preventing further treatment	1	1
disease progression	38	34
symptomatic deterioration	3	4

## Baseline characteristics

### Reporting groups

Reporting group title	GemcitabineDocetaxel
Reporting group description: Gemcitabine 675 mg/m <sup>2</sup> i.v. days 1 and 8, docetaxel 75 mg/m <sup>2</sup> i.v. day 8 every three weeks for up to 6 cycles	
Reporting group title	Doxorubicin
Reporting group description: Doxorubicin 75 mg/m <sup>2</sup> i.v. day 1 every three weeks for up to 6 cycles	

Reporting group values	GemcitabineDocetaxel	Doxorubicin	Total
Number of subjects	128	129	257
Age categorical			
Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	98	99	197
From 65-84 years	30	30	60
85 years and over	0	0	0
Gender categorical			
Units: Subjects			
Female	77	79	156
Male	51	50	101
WHO performance status			
Units: Subjects			
0 - Fully active	52	55	107
1 - Ambulatory (work able)	67	63	130
2 - Ambulatory (not work able)	9	11	20
Trojani grade			
Units: Subjects			
Grade 2	34	29	63
Grade 3	85	85	170
Not known	9	15	24
Histology			
"Other eligible sarcomas" contained 47 non-uterine leiomyosarcoma (23 gemcitabine & docetaxel, 24 doxorubicin).			
Units: Subjects			
Uterine leiomyosarcoma	35	36	71
Synovial sarcoma	6	5	11
Pleomorphic sarcoma	16	16	32
Other eligible sarcomas	71	72	143

## End points

### End points reporting groups

Reporting group title	GemcitabineDocetaxel
Reporting group description:	Gemcitabine 675 mg/m <sup>2</sup> i.v. days 1 and 8, docetaxel 75 mg/m <sup>2</sup> i.v. day 8 every three weeks for up to 6 cycles
Reporting group title	Doxorubicin
Reporting group description:	Doxorubicin 75 mg/m <sup>2</sup> i.v. day 1 every three weeks for up to 6 cycles

### Primary: Progression free survival at 24 weeks

End point title	Progression free survival at 24 weeks
End point description:	The primary endpoint for the trial was the proportion of patients who were alive and progression free at 24 weeks post-randomisation. The 24 week Kaplan-Meier progression free survival rates are reported for each arm.
End point type	Primary
End point timeframe:	24 weeks after the date of randomisation

End point values	GemcitabineDo cetaxel	Doxorubicin		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	128	129		
Units: percentage				
number (confidence interval 95%)	0.464 (0.375 to 0.548)	0.463 (0.375 to 0.546)		

### Statistical analyses

Statistical analysis title	Progression free survival at 24 weeks
Statistical analysis description:	The sample size was based on a comparison of proportions. As there was censoring before the week 24 time point, Kaplan-Meier rates have been provided and used for the test of proportions in this section. The following are the results if we remove censored patients and perform a standard test of proportions: Doxorubicin: 59/127 progression free - 46.5% (37.7% - 55.2%) Gemcitabine & Docetaxel: 57/123 progression free - 46.3% (37.4% - 55.3%) p=0.99. Conclusions are the same.
Comparison groups	GemcitabineDocetaxel v Doxorubicin

Number of subjects included in analysis	257
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.99 <sup>[1]</sup>
Method	t-test, 2-sided
Parameter estimate	Mean difference (final values)
Point estimate	-0.001
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.123
upper limit	0.121

Notes:

[1] - Conclusions are exactly the same if we do a standard test of proportions or using the K-M rates as we have here.

### Secondary: Progression free survival at 12 weeks

End point title	Progression free survival at 12 weeks
End point description: The 12 week Kaplan-Meier progression free survival rates are reported for each arm.	
End point type	Secondary
End point timeframe: 12 weeks from date of randomisation.	

End point values	GemcitabineDo cetaxel	Doxorubicin		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	128	129		
Units: percentage				
number (confidence interval 95%)	0.638 (0.548 to 0.715)	0.721 (0.635 to 0.790)		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Progression free survival

End point title	Progression free survival
End point description: Kaplan-Meier median progression free survival rates are reported for each arm as well as the hazard ratio comparing the two arms.	
End point type	Secondary
End point timeframe: Entire follow up period.	

<b>End point values</b>	GemcitabineDo cetaxel	Doxorubicin		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	128	129		
Units: weeks				
median (confidence interval 95%)	23.7 (18.1 to 28.0)	23.3 (19.6 to 30.4)		

## Statistical analyses

<b>Statistical analysis title</b>	PFS hazard ratio
-----------------------------------	------------------

Statistical analysis description:

Hazard ratio comparing PFS curves (Gemcitabine & Docetaxel vs Doxorubicin).

The hazard ratio reported is from an unadjusted comparison. After adjusting for histological subtype, the HR was 1.26 (0.97–1.63; p=0.08).

Comparison groups	GemcitabineDocetaxel v Doxorubicin
Number of subjects included in analysis	257
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.06
Method	Regression, Cox
Parameter estimate	Hazard ratio (HR)
Point estimate	1.28
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.99
upper limit	1.65

## Secondary: Overall survival

End point title	Overall survival
-----------------	------------------

End point description:

The median overall survival Kaplan-Meier estimates are reported for each arm as well as the hazard ratio comparing the two curves.

End point type	Secondary
----------------	-----------

End point timeframe:

Entire follow up period.

<b>End point values</b>	GemcitabineDo cetaxel	Doxorubicin		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	128	129		
Units: weeks				
median (confidence interval 95%)	67.3 (53.1 to 83.1)	76.3 (60.0 to 91.3)		

## Statistical analyses

<b>Statistical analysis title</b>	OS hazard ratio
Statistical analysis description:	
Hazard ratio comparing OS curves (Gemcitabine & Docetaxel vs Doxorubicin). The hazard ratio reported is from an unadjusted comparison.	
Comparison groups	GemcitabineDocetaxel v Doxorubicin
Number of subjects included in analysis	257
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.41
Method	Regression, Cox
Parameter estimate	Hazard ratio (HR)
Point estimate	1.14
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.83
upper limit	1.57

## Secondary: Objective response by RECIST 1.1

End point title	Objective response by RECIST 1.1
End point description:	
End point type	Secondary
End point timeframe:	
Patients were assessed at 12 weeks post-randomisation, 24 weeks post-randomisation and then approximately every 12 weeks until disease progression or 24 months post-randomisation.	

<b>End point values</b>	GemcitabineDo cetaxel	Doxorubicin		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	128	129		
Units: patients				
Complete Response (CR)	0	2		
Partial Response (PR)	25	23		
Stable Disease (SD)	50	60		
Progressive Disease (PD)	27	25		
Not Evaluable	26	19		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Quality of life at 12 weeks

End point title	Quality of life at 12 weeks
-----------------	-----------------------------

End point description:

Here we report details of the difference between treatment arms in Global Health Status score at 12 weeks.

Further details of differences in quality of life at 12 weeks were reported in the main trial paper. There was no evidence to suggest that quality of life measures differed between the two treatment groups.

End point type	Secondary
----------------	-----------

End point timeframe:

12 weeks post-randomisation.

End point values	GemcitabineDocetaxel	Doxorubicin		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	63	64		
Units: score				
arithmetic mean (standard deviation)	59.1 ( $\pm$ 21.8)	63.8 ( $\pm$ 22.5)		

## Statistical analyses

Statistical analysis title	Difference in mean Global Health Status score
----------------------------	---

Statistical analysis description:

From a linear regression model, adjusting for baseline score, histological subtype, and time since baseline.

Treatment effect is calculated as: (gemcitabine and docetaxel change from baseline) – (doxorubicin change from baseline).

Comparison groups	GemcitabineDocetaxel v Doxorubicin
-------------------	------------------------------------

Number of subjects included in analysis	127
---	-----

Analysis specification	Pre-specified
------------------------	---------------

Analysis type	superiority
---------------	-------------

P-value	= 0.17
---------	--------

Method	Regression, Linear
--------	--------------------

Parameter estimate	Mean difference (final values)
--------------------	--------------------------------

Point estimate	-5.1
----------------	------

---

Confidence interval	
level	95 %
sides	2-sided
lower limit	-15
upper limit	4.7

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

All adverse events (including serious adverse events) that occurred between informed consent and 30 days post last trial treatment administration were recorded.

Adverse event reporting additional description:

Adverse events pertaining to the trial drugs were closely monitored throughout the trial. Each patients GP was informed of their participation and asked to report all serious side effects immediately to sites. Patient contact cards and adverse event diaries were also issued to patients and reviewed before each treatment.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	CTCAE
-----------------	-------

Dictionary version	4.03
--------------------	------

### Reporting groups

Reporting group title	GemcitabineDocetaxel
-----------------------	----------------------

Reporting group description:

Gemcitabine 675 mg/m<sup>2</sup> i.v. days 1 and 8, docetaxel 75 mg/m<sup>2</sup> i.v. day 8 every three weeks for up to 6 cycles

Reporting group title	Doxorubicin
-----------------------	-------------

Reporting group description:

Doxorubicin 75 mg/m<sup>2</sup> i.v. day 1 every three weeks for up to 6 cycles

<b>Serious adverse events</b>	GemcitabineDocetaxel	Doxorubicin	
Total subjects affected by serious adverse events			
subjects affected / exposed	71 / 126 (56.35%)	69 / 128 (53.91%)	
number of deaths (all causes)	80	74	
number of deaths resulting from adverse events	3	3	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Tumour pain			
subjects affected / exposed	0 / 126 (0.00%)	1 / 128 (0.78%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular disorders			
Hot flashes			
subjects affected / exposed	0 / 126 (0.00%)	1 / 128 (0.78%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thromboembolic event			

subjects affected / exposed	4 / 126 (3.17%)	9 / 128 (7.03%)	
occurrences causally related to treatment / all	1 / 4	5 / 9	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>General disorders and administration site conditions</b>			
<b>Oedema limbs</b>			
subjects affected / exposed	2 / 126 (1.59%)	0 / 128 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Fatigue</b>			
subjects affected / exposed	0 / 126 (0.00%)	1 / 128 (0.78%)	
occurrences causally related to treatment / all	0 / 0	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Fever</b>			
subjects affected / exposed	15 / 126 (11.90%)	14 / 128 (10.94%)	
occurrences causally related to treatment / all	10 / 19	13 / 18	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Non-cardiac chest pain</b>			
subjects affected / exposed	2 / 126 (1.59%)	4 / 128 (3.13%)	
occurrences causally related to treatment / all	0 / 2	2 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Pain</b>			
subjects affected / exposed	1 / 126 (0.79%)	1 / 128 (0.78%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Sudden death NOS</b>			
subjects affected / exposed	1 / 126 (0.79%)	1 / 128 (0.78%)	
occurrences causally related to treatment / all	1 / 1	1 / 1	
deaths causally related to treatment / all	1 / 1	1 / 1	
<b>Immune system disorders</b>			
<b>Bronchial infection</b>			
subjects affected / exposed	2 / 126 (1.59%)	1 / 128 (0.78%)	
occurrences causally related to treatment / all	1 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Reproductive system and breast disorders			
Female genital tract fistula			
subjects affected / exposed	1 / 126 (0.79%)	0 / 128 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pelvic pain			
subjects affected / exposed	1 / 126 (0.79%)	0 / 128 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	1 / 126 (0.79%)	1 / 128 (0.78%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dyspnoea			
subjects affected / exposed	5 / 126 (3.97%)	3 / 128 (2.34%)	
occurrences causally related to treatment / all	0 / 5	3 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pleuritic pain			
subjects affected / exposed	0 / 126 (0.00%)	1 / 128 (0.78%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonitis			
subjects affected / exposed	1 / 126 (0.79%)	0 / 128 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumothorax			
subjects affected / exposed	0 / 126 (0.00%)	1 / 128 (0.78%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psychiatric disorders			
Confusion			

subjects affected / exposed	0 / 126 (0.00%)	1 / 128 (0.78%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Investigations</b>			
Blood bilirubin increased			
subjects affected / exposed	0 / 126 (0.00%)	1 / 128 (0.78%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neutrophil count decreased			
subjects affected / exposed	10 / 126 (7.94%)	18 / 128 (14.06%)	
occurrences causally related to treatment / all	10 / 10	22 / 22	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Cardiac disorders</b>			
Chest pain - cardiac			
subjects affected / exposed	1 / 126 (0.79%)	0 / 128 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Heart failure			
subjects affected / exposed	0 / 126 (0.00%)	1 / 128 (0.78%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Left ventricular systolic dysfunction			
subjects affected / exposed	0 / 126 (0.00%)	1 / 128 (0.78%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myocardial infarction			
subjects affected / exposed	1 / 126 (0.79%)	1 / 128 (0.78%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Palpitations			
subjects affected / exposed	0 / 126 (0.00%)	1 / 128 (0.78%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Nervous system disorders</b>			

Seizure			
subjects affected / exposed	0 / 126 (0.00%)	1 / 128 (0.78%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Syncope			
subjects affected / exposed	0 / 126 (0.00%)	2 / 128 (1.56%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tremor			
subjects affected / exposed	0 / 126 (0.00%)	1 / 128 (0.78%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	4 / 126 (3.17%)	6 / 128 (4.69%)	
occurrences causally related to treatment / all	4 / 4	5 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Febrile neutropenia			
subjects affected / exposed	15 / 126 (11.90%)	26 / 128 (20.31%)	
occurrences causally related to treatment / all	14 / 15	26 / 27	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	4 / 126 (3.17%)	1 / 128 (0.78%)	
occurrences causally related to treatment / all	1 / 6	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ascites			
subjects affected / exposed	1 / 126 (0.79%)	0 / 128 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bloating			
subjects affected / exposed	1 / 126 (0.79%)	0 / 128 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Colonic ulcer			
subjects affected / exposed	0 / 126 (0.00%)	1 / 128 (0.78%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Constipation			
subjects affected / exposed	1 / 126 (0.79%)	4 / 128 (3.13%)	
occurrences causally related to treatment / all	0 / 1	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diarrhoea			
subjects affected / exposed	9 / 126 (7.14%)	5 / 128 (3.91%)	
occurrences causally related to treatment / all	7 / 9	3 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dyspepsia			
subjects affected / exposed	1 / 126 (0.79%)	0 / 128 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophageal haemorrhage			
subjects affected / exposed	0 / 126 (0.00%)	1 / 128 (0.78%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diverticulitis			
alternative dictionary used: MedDRA 21			
subjects affected / exposed	1 / 126 (0.79%)	0 / 128 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oral candidiasis			
alternative dictionary used: MedDRA 21			
subjects affected / exposed	0 / 126 (0.00%)	1 / 128 (0.78%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nausea			

subjects affected / exposed	2 / 126 (1.59%)	4 / 128 (3.13%)	
occurrences causally related to treatment / all	2 / 2	4 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Small intestinal obstruction			
subjects affected / exposed	1 / 126 (0.79%)	0 / 128 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vomiting			
subjects affected / exposed	5 / 126 (3.97%)	3 / 128 (2.34%)	
occurrences causally related to treatment / all	2 / 5	3 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin and subcutaneous tissue disorders			
Skin reaction	Additional description: reaction at Hickman line site		
alternative dictionary used: MedDRA 21			
subjects affected / exposed	0 / 126 (0.00%)	1 / 128 (0.78%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin ulceration			
subjects affected / exposed	1 / 126 (0.79%)	0 / 128 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal and urinary disorders			
Urinary retention			
subjects affected / exposed	1 / 126 (0.79%)	0 / 128 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	1 / 126 (0.79%)	1 / 128 (0.78%)	
occurrences causally related to treatment / all	1 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myalgia			

subjects affected / exposed	1 / 126 (0.79%)	0 / 128 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pain in extremity			
subjects affected / exposed	1 / 126 (0.79%)	0 / 128 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Anorectal infection			
subjects affected / exposed	0 / 126 (0.00%)	1 / 128 (0.78%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Catheter related infection			
subjects affected / exposed	1 / 126 (0.79%)	0 / 128 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infection			
alternative dictionary used: MedDRA 21			
subjects affected / exposed	2 / 126 (1.59%)	1 / 128 (0.78%)	
occurrences causally related to treatment / all	2 / 3	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Escherichia infection			
alternative dictionary used: MedDRA 21			
subjects affected / exposed	1 / 126 (0.79%)	0 / 128 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal infection			
alternative dictionary used: MedDRA 21			
subjects affected / exposed	1 / 126 (0.79%)	0 / 128 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Device related infection	Additional description: Hickman line infection		
alternative dictionary used: MedDRA 21			

subjects affected / exposed	0 / 126 (0.00%)	1 / 128 (0.78%)	
occurrences causally related to treatment / all	0 / 0	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Varicella zoster virus infection			
alternative dictionary used: MedDRA 21			
subjects affected / exposed	0 / 126 (0.00%)	1 / 128 (0.78%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Viral infection			
alternative dictionary used: MedDRA 21			
subjects affected / exposed	0 / 126 (0.00%)	1 / 128 (0.78%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung infection			
subjects affected / exposed	5 / 126 (3.97%)	5 / 128 (3.91%)	
occurrences causally related to treatment / all	2 / 5	5 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nail infection			
subjects affected / exposed	1 / 126 (0.79%)	0 / 128 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pharyngitis			
subjects affected / exposed	0 / 126 (0.00%)	1 / 128 (0.78%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sepsis			
subjects affected / exposed	1 / 126 (0.79%)	2 / 128 (1.56%)	
occurrences causally related to treatment / all	1 / 1	2 / 2	
deaths causally related to treatment / all	1 / 1	1 / 1	
Cellulitis			
subjects affected / exposed	2 / 126 (1.59%)	0 / 128 (0.00%)	
occurrences causally related to treatment / all	2 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Skin infection			
subjects affected / exposed	2 / 126 (1.59%)	1 / 128 (0.78%)	
occurrences causally related to treatment / all	0 / 3	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Upper respiratory infection			
subjects affected / exposed	3 / 126 (2.38%)	3 / 128 (2.34%)	
occurrences causally related to treatment / all	1 / 3	2 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary tract infection			
subjects affected / exposed	2 / 126 (1.59%)	0 / 128 (0.00%)	
occurrences causally related to treatment / all	2 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wound infection			
subjects affected / exposed	1 / 126 (0.79%)	1 / 128 (0.78%)	
occurrences causally related to treatment / all	1 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolism and nutrition disorders			
Hypercalcaemia			
subjects affected / exposed	0 / 126 (0.00%)	1 / 128 (0.78%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypokalaemia			
subjects affected / exposed	1 / 126 (0.79%)	0 / 128 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 1 %

<b>Non-serious adverse events</b>	GemcitabineDocetaxel	Doxorubicin	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	126 / 126 (100.00%)	128 / 128 (100.00%)	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			

Tumour pain subjects affected / exposed occurrences (all)	3 / 126 (2.38%) 3	2 / 128 (1.56%) 2	
Vascular disorders Hypertension subjects affected / exposed occurrences (all)	1 / 126 (0.79%) 1	2 / 128 (1.56%) 2	
Thromboembolic event subjects affected / exposed occurrences (all)	4 / 126 (3.17%) 4	8 / 128 (6.25%) 8	
General disorders and administration site conditions Fatigue subjects affected / exposed occurrences (all)	108 / 126 (85.71%) 108	116 / 128 (90.63%) 116	
Pain subjects affected / exposed occurrences (all)	79 / 126 (62.70%) 79	80 / 128 (62.50%) 80	
Fever subjects affected / exposed occurrences (all)	28 / 126 (22.22%) 28	25 / 128 (19.53%) 25	
Oedema limbs subjects affected / exposed occurrences (all)	55 / 126 (43.65%) 55	24 / 128 (18.75%) 24	
Non-cardiac chest pain subjects affected / exposed occurrences (all)	2 / 126 (1.59%) 2	1 / 128 (0.78%) 1	
Infusion related reaction subjects affected / exposed occurrences (all)	5 / 126 (3.97%) 5	0 / 128 (0.00%) 0	
Sudden death NOS subjects affected / exposed occurrences (all)	1 / 126 (0.79%) 1	0 / 128 (0.00%) 0	
Immune system disorders Allergic reaction subjects affected / exposed occurrences (all)	4 / 126 (3.17%) 4	1 / 128 (0.78%) 1	

Anaphylaxis subjects affected / exposed occurrences (all)	1 / 126 (0.79%) 1	0 / 128 (0.00%) 0	
Reproductive system and breast disorders Breast pain subjects affected / exposed occurrences (all)  Premature menopause subjects affected / exposed occurrences (all)	0 / 126 (0.00%) 0  0 / 126 (0.00%) 0	1 / 128 (0.78%) 1  1 / 128 (0.78%) 1	
Respiratory, thoracic and mediastinal disorders Cough subjects affected / exposed occurrences (all)  Dyspnoea subjects affected / exposed occurrences (all)  Pneumonitis subjects affected / exposed occurrences (all)  Epistaxis subjects affected / exposed occurrences (all)  Hiccups subjects affected / exposed occurrences (all)  Pleural effusion subjects affected / exposed occurrences (all)  Bronchopulmonary haemorrhage subjects affected / exposed occurrences (all)  Pneumothorax subjects affected / exposed occurrences (all)	26 / 126 (20.63%) 26  29 / 126 (23.02%) 29  8 / 126 (6.35%) 8  13 / 126 (10.32%) 13  3 / 126 (2.38%) 3  2 / 126 (1.59%) 2  0 / 126 (0.00%) 0  0 / 126 (0.00%) 0	24 / 128 (18.75%) 24  19 / 128 (14.84%) 19  4 / 128 (3.13%) 4  2 / 128 (1.56%) 2  2 / 128 (1.56%) 2  1 / 128 (0.78%) 1  1 / 128 (0.78%) 1  1 / 128 (0.78%) 1	
Psychiatric disorders			

Insomnia subjects affected / exposed occurrences (all)	10 / 126 (7.94%) 10	10 / 128 (7.81%) 10	
Investigations			
White blood cell decreased subjects affected / exposed occurrences (all)	63 / 126 (50.00%) 63	43 / 128 (33.59%) 43	
Neutrophil count decreased subjects affected / exposed occurrences (all)	71 / 126 (56.35%) 71	58 / 128 (45.31%) 58	
Platelet count decreased subjects affected / exposed occurrences (all)	31 / 126 (24.60%) 31	14 / 128 (10.94%) 14	
Alkaline phosphatase increased subjects affected / exposed occurrences (all)	48 / 126 (38.10%) 48	43 / 128 (33.59%) 43	
Alanine aminotransferase increased subjects affected / exposed occurrences (all)	37 / 126 (29.37%) 37	35 / 128 (27.34%) 35	
Aspartate aminotransferase increased subjects affected / exposed occurrences (all)	13 / 126 (10.32%) 13	14 / 128 (10.94%) 14	
GGT increased subjects affected / exposed occurrences (all)	0 / 126 (0.00%) 0	1 / 128 (0.78%) 1	
Urea increased alternative dictionary used: MedDRA 22.1 subjects affected / exposed occurrences (all)	12 / 126 (9.52%) 12	11 / 128 (8.59%) 11	
Blood creatinine decreased alternative dictionary used: MedDRA 22.1 subjects affected / exposed occurrences (all)	0 / 126 (0.00%) 0	1 / 128 (0.78%) 1	
Injury, poisoning and procedural complications			

Vascular access complication subjects affected / exposed occurrences (all)	1 / 126 (0.79%) 1	2 / 128 (1.56%) 2	
Fracture subjects affected / exposed occurrences (all)	1 / 126 (0.79%) 1	0 / 128 (0.00%) 0	
Radiation recall reaction (dermatologic) subjects affected / exposed occurrences (all)	1 / 126 (0.79%) 1	0 / 128 (0.00%) 0	
Cardiac disorders			
Chest pain - cardiac subjects affected / exposed occurrences (all)	2 / 126 (1.59%) 2	1 / 128 (0.78%) 1	
Heart failure subjects affected / exposed occurrences (all)	0 / 126 (0.00%) 0	1 / 128 (0.78%) 1	
Left ventricular systolic dysfunction subjects affected / exposed occurrences (all)	0 / 126 (0.00%) 0	1 / 128 (0.78%) 1	
Myocardial infarction subjects affected / exposed occurrences (all)	1 / 126 (0.79%) 1	1 / 128 (0.78%) 1	
Nervous system disorders			
Dysgeusia subjects affected / exposed occurrences (all)	25 / 126 (19.84%) 25	24 / 128 (18.75%) 24	
Peripheral sensory neuropathy subjects affected / exposed occurrences (all)	31 / 126 (24.60%) 31	14 / 128 (10.94%) 14	
Dizziness subjects affected / exposed occurrences (all)	4 / 126 (3.17%) 4	10 / 128 (7.81%) 10	
Syncope subjects affected / exposed occurrences (all)	0 / 126 (0.00%) 0	3 / 128 (2.34%) 3	
Tremor			

subjects affected / exposed occurrences (all)	0 / 126 (0.00%) 0	1 / 128 (0.78%) 1	
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	112 / 126 (88.89%)	101 / 128 (78.91%)	
occurrences (all)	112	101	
Febrile neutropenia			
subjects affected / exposed	15 / 126 (11.90%)	26 / 128 (20.31%)	
occurrences (all)	15	26	
Gastrointestinal disorders			
Nausea			
subjects affected / exposed	72 / 126 (57.14%)	87 / 128 (67.97%)	
occurrences (all)	72	87	
Mucositis oral			
subjects affected / exposed	61 / 126 (48.41%)	82 / 128 (64.06%)	
occurrences (all)	61	82	
Constipation			
subjects affected / exposed	51 / 126 (40.48%)	55 / 128 (42.97%)	
occurrences (all)	51	55	
Diarrhoea			
subjects affected / exposed	52 / 126 (41.27%)	50 / 128 (39.06%)	
occurrences (all)	52	50	
Vomiting			
subjects affected / exposed	32 / 126 (25.40%)	49 / 128 (38.28%)	
occurrences (all)	32	49	
Dyspepsia			
subjects affected / exposed	18 / 126 (14.29%)	28 / 128 (21.88%)	
occurrences (all)	18	28	
Abdominal pain			
subjects affected / exposed	16 / 126 (12.70%)	20 / 128 (15.63%)	
occurrences (all)	16	20	
Dry mouth			
subjects affected / exposed	5 / 126 (3.97%)	12 / 128 (9.38%)	
occurrences (all)	5	12	
Rectal haemorrhage			

subjects affected / exposed	3 / 126 (2.38%)	1 / 128 (0.78%)
occurrences (all)	3	1
Colonic ulcer		
subjects affected / exposed	0 / 126 (0.00%)	1 / 128 (0.78%)
occurrences (all)	0	1
Lower gastrointestinal haemorrhage		
subjects affected / exposed	0 / 126 (0.00%)	1 / 128 (0.78%)
occurrences (all)	0	1
Oral candidiasis		
subjects affected / exposed	0 / 126 (0.00%)	1 / 128 (0.78%)
occurrences (all)	0	1
Abdominal distension		
subjects affected / exposed	5 / 126 (3.97%)	0 / 128 (0.00%)
occurrences (all)	5	0
Ascites		
subjects affected / exposed	1 / 126 (0.79%)	0 / 128 (0.00%)
occurrences (all)	1	0
Diverticulitis		
alternative dictionary used: MedDRA 21		
subjects affected / exposed	1 / 126 (0.79%)	0 / 128 (0.00%)
occurrences (all)	1	0
Small intestinal obstruction		
subjects affected / exposed	1 / 126 (0.79%)	0 / 128 (0.00%)
occurrences (all)	1	0
Rectal tenesmus		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	1 / 126 (0.79%)	0 / 128 (0.00%)
occurrences (all)	1	0
Intestinal perforation		
alternative dictionary used: MedDRA 22.1		
subjects affected / exposed	0 / 126 (0.00%)	1 / 128 (0.78%)
occurrences (all)	0	1
Skin and subcutaneous tissue disorders		
Alopecia		

subjects affected / exposed occurrences (all)	95 / 126 (75.40%) 95	110 / 128 (85.94%) 110	
Urticaria subjects affected / exposed occurrences (all)	1 / 126 (0.79%) 1	1 / 128 (0.78%) 1	
Skin ulceration subjects affected / exposed occurrences (all)	3 / 126 (2.38%) 3	0 / 128 (0.00%) 0	
Rash alternative dictionary used: MedDRA 22.1 subjects affected / exposed occurrences (all)	16 / 126 (12.70%) 16	3 / 128 (2.34%) 3	
Lichen sclerosus alternative dictionary used: MedDRA 22.1 subjects affected / exposed occurrences (all)	0 / 126 (0.00%) 0	1 / 128 (0.78%) 1	
Night sweats alternative dictionary used: MedDRA 22.1 subjects affected / exposed occurrences (all)	1 / 126 (0.79%) 1	0 / 128 (0.00%) 0	
Renal and urinary disorders Acute kidney injury subjects affected / exposed occurrences (all)	0 / 126 (0.00%) 0	1 / 128 (0.78%) 1	
Renal vein thrombosis alternative dictionary used: MedDRA 22.1 subjects affected / exposed occurrences (all)	0 / 126 (0.00%) 0	1 / 128 (0.78%) 1	
Musculoskeletal and connective tissue disorders Back pain subjects affected / exposed occurrences (all)	12 / 126 (9.52%) 12	12 / 128 (9.38%) 12	
Myalgia subjects affected / exposed occurrences (all)	12 / 126 (9.52%) 12	5 / 128 (3.91%) 5	

Muscle weakness lower limb subjects affected / exposed occurrences (all)	2 / 126 (1.59%) 2	2 / 128 (1.56%) 2	
Bone pain subjects affected / exposed occurrences (all)	0 / 126 (0.00%) 0	1 / 128 (0.78%) 1	
<b>Infections and infestations</b>			
Urinary tract infection subjects affected / exposed occurrences (all)	8 / 126 (6.35%) 8	9 / 128 (7.03%) 9	
Lower respiratory tract infection alternative dictionary used: MedDRA 21 subjects affected / exposed occurrences (all)	6 / 126 (4.76%) 6	4 / 128 (3.13%) 4	
Varicella zoster virus infection alternative dictionary used: MedDRA 21 subjects affected / exposed occurrences (all)	0 / 126 (0.00%) 0	3 / 128 (2.34%) 3	
Nail infection subjects affected / exposed occurrences (all)	1 / 126 (0.79%) 1	2 / 128 (1.56%) 2	
Lung infection subjects affected / exposed occurrences (all)	4 / 126 (3.17%) 4	5 / 128 (3.91%) 5	
Upper respiratory infection subjects affected / exposed occurrences (all)	2 / 126 (1.59%) 2	2 / 128 (1.56%) 2	
Infection alternative dictionary used: MedDRA 21 subjects affected / exposed occurrences (all)	3 / 126 (2.38%) 3	1 / 128 (0.78%) 1	
Skin infection subjects affected / exposed occurrences (all)	2 / 126 (1.59%) 2	1 / 128 (0.78%) 1	
Wound infection			

subjects affected / exposed	1 / 126 (0.79%)	1 / 128 (0.78%)	
occurrences (all)	1	1	
Device related infection			
alternative dictionary used: MedDRA 21			
subjects affected / exposed	0 / 126 (0.00%)	1 / 128 (0.78%)	
occurrences (all)	0	1	
Cellulitis			
subjects affected / exposed	4 / 126 (3.17%)	0 / 128 (0.00%)	
occurrences (all)	4	0	
Bronchial infection			
subjects affected / exposed	3 / 126 (2.38%)	0 / 128 (0.00%)	
occurrences (all)	3	0	
Catheter related infection			
subjects affected / exposed	1 / 126 (0.79%)	0 / 128 (0.00%)	
occurrences (all)	1	0	
Escherichia infection			
alternative dictionary used: MedDRA 21			
subjects affected / exposed	1 / 126 (0.79%)	0 / 128 (0.00%)	
occurrences (all)	1	0	
Sepsis			
subjects affected / exposed	1 / 126 (0.79%)	2 / 128 (1.56%)	
occurrences (all)	1	2	
Anal abscess			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	0 / 126 (0.00%)	1 / 128 (0.78%)	
occurrences (all)	0	1	
Stoma site abscess			
alternative dictionary used: MedDRA 22.1			
subjects affected / exposed	1 / 126 (0.79%)	0 / 128 (0.00%)	
occurrences (all)	1	0	
Metabolism and nutrition disorders			
Anorexia			
subjects affected / exposed	56 / 126 (44.44%)	63 / 128 (49.22%)	
occurrences (all)	56	63	
Hypoalbuminaemia			

subjects affected / exposed occurrences (all)	40 / 126 (31.75%) 40	28 / 128 (21.88%) 28
Hyponatraemia subjects affected / exposed occurrences (all)	25 / 126 (19.84%) 25	20 / 128 (15.63%) 20
Hyperkalaemia subjects affected / exposed occurrences (all)	18 / 126 (14.29%) 18	11 / 128 (8.59%) 11
Hypokalaemia subjects affected / exposed occurrences (all)	8 / 126 (6.35%) 8	9 / 128 (7.03%) 9
Hyperglycaemia subjects affected / exposed occurrences (all)	3 / 126 (2.38%) 3	1 / 128 (0.78%) 1
Hypercalcaemia subjects affected / exposed occurrences (all)	0 / 126 (0.00%) 0	1 / 128 (0.78%) 1
Electrolyte imbalance alternative dictionary used: MedDRA 22.1 subjects affected / exposed occurrences (all)	1 / 126 (0.79%) 1	0 / 128 (0.00%) 0
Fluid retention alternative dictionary used: MedDRA 22.1 subjects affected / exposed occurrences (all)	1 / 126 (0.79%) 1	0 / 128 (0.00%) 0

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
13 April 2011	Protocol: Update on contraception requirements Clarification on dose modifications for haematological toxicity PIS: Clarification of timepoints for CT/MRI scans, and radiation risk to patients Clarification that consent to allow genetic testing on research blood & tissue samples is optional
21 October 2011	Protocol - Inclusion criteria: Histological confirmation wording changed to clarify high grade disease Chemotherapy wording changed to clarify no previous chemotherapy for sarcoma and no doxorubicin for any previous cancer ALP wording clarified
08 March 2013	Protocol: Addition of secondary endpoint (Time from start of treatment to progression or death (whichever occurs first))
23 March 2016	Protocol: Addition of guidance to allow patients who have not progressed after 24 months on trial be scanned according to local site practice
25 January 2019	Protocol: Translational Research section updated to include information on some additional exploratory research that is planned to be performed on the stored blood and tissue samples

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

Non-serious AEs: includes SAEs and non-serious AEs  
Non-serious AEs: highest grade experienced by patients collected, therefore 'subjects affected' number has been entered in 'occurrences'

Notes:

---

### Online references

<http://www.ncbi.nlm.nih.gov/pubmed/28882536>